4.6 Article

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer

Journal

BMC CANCER
Volume 15, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12885-015-1386-7

Keywords

Circulating tumor cells; EMT; Breast cancer; Keratin expression levels; Fluorescence levels of cell markers; Vimentin/keratin ratio

Categories

Funding

  1. Greek General Secretary of Research and Technology [KA3175]

Ask authors/readers for more resources

Background: CTCs expressing variable levels of epithelial and mesenchymal markers in breast cancer have previously been reported. However, no information exists for keratin expression levels of CTCs in association with disease status, whereas assays for the characterization of transitional EMT phenotypes of CTCs in breast cancer are rather lacking. We investigated the correlation between keratin expression of CTCs and patients' outcome and characterized the EMT status of CTCs via the establishment of a numerical ratio value of keratin and vimentin expression levels on a single cell basis. Methods: Keratin expression was evaluated in 1262 CTCs from 61 CTC-positive patients with metastatic breast cancer, using analysis of images obtained through the CellSearch System. For the determination of vimentin/keratin (vim/K) ratios, expression levels of keratin and vimentin were measured in cytospin preparations of luminal (MCF-7 and T47D) and basal (MDA.MB231 and Hs578T) breast cancer cell lines and 110 CTCs from 5 CTC-positive patients using triple immunofluorescence laser scanning microscopy and image analysis. Results: MCF-7 and T47D displayed lower vim/K ratios compared to MDA.MB231 and Hs578T cells, while MCF-7 cells that had experimentally undergone EMT were characterized by varying intermediate vim/K ratios. CTCs were consisted of an heterogeneous population presenting variable vim/K values with 46% of them being in the range of luminal breast cancer cell lines. Keratin expression levels of CTCs detected by the CellSearch System correlated with triple negative (p = 0.039) and ER-negative (p = 0.025) breast cancer, and overall survival (p = 0.038). Conclusions: Keratin expression levels of CTCs correlate with tumor characteristics and clinical outcome. Moreover, CTCs display significant heterogeneity in terms of the degree of EMT phenotype that probably reflects differential invasive potential. The assessment of the vim/K ratios as a surrogate marker for the EMT status of CTCs merits further investigation as a prognostic tool in breast cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period

Alexios Matikas, Athanasios Kotsakis, Maria Perraki, Dora Hatzidaki, Konstantinos Kalbakis, Emmanouil Kontopodis, Michail Nikolaou, Vasilios Georgoulias

Summary: This study investigated the efficacy of subsequent treatment lines for metastatic breast cancer (MBC) and the association between radiologic objective response rate (ORR) and overall survival (OS). Results showed limited efficacy in late treatment lines for MBC, while response to first-line therapy was associated with long-term survival.

BREAST CARE (2022)

Article Oncology

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer

Alexios Matikas, Athanasios Kotsakis, Stella Apostolaki, Helen Politaki, Maria Perraki, Kostas Kalbakis, Michalis Nikolaou, Panagiota Economopoulou, Dora Hatzidaki, Vassilis Georgoulias

Summary: This study found that baseline CTC positivity is associated with shorter overall survival in breast cancer patients. CTC positivity predicts early recurrence but not late recurrence. Following adjuvant chemotherapy, more patients convert from CTC-positive to CTC-negative. CTC status at follow-up predicts disease recurrence.

BRITISH JOURNAL OF CANCER (2022)

Article Chemistry, Multidisciplinary

Acoustic Array Biochip Combined with Allele-Specific PCR for Multiple Cancer Mutation Analysis in Tissue and Liquid Biopsy

Nikoletta Naoumi, Kleita Michaelidou, George Papadakis, Agapi E. Simaiaki, Roman Fernandez, Maria Calero, Antonio Arnau, Achilleas Tsortos, Sofia Agelaki, Electra Gizeli

Summary: Regular screening of cancer point mutations is crucial for cancer management and treatment selection. A new method combining allele-specific PCR and a high fundamental frequency quartz crystal microbalance array has been developed, which can detect mutations in a fast and cost-effective manner. The method has shown high sensitivity and good agreement with results from real samples.

ACS SENSORS (2022)

Meeting Abstract Oncology

Longitudinal proteogenomic profiling reveals therapeutic vulnerabilities of immunometabolism in breast cancer

K. Wang, I. Zerdes, E. G. Sifakis, H. J. Johansson, A. Mezheyeuski, J. Lehtio, J. Bergh, T. Hatschek, A. Matikas, T. Foukakis

ANNALS OF ONCOLOGY (2022)

Article Oncology

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study

Caroline Boman, Luisa Edman Kessler, Jonas Bergh, Alexios Matikas, Theodoros Foukakis

Summary: Despite therapeutic advances, overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement. A population-based retrospective study identified characteristics of patients with very short survival time following MBC diagnosis.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Letter Oncology

Response to A. Chauhan and A. Pal

Alexios Matikas, Vassilis Georgoulias

BRITISH JOURNAL OF CANCER (2022)

Meeting Abstract Oncology

Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC)

Kang Wang, Aafke Duinmeijer, Alexios Matikas, Renske Altena, Hemming Johansson, Hanna Fredholm, Theodoros Foukakis

CANCER RESEARCH (2022)

Review Oncology

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution

Evangelos Tzoras, Ioannis Zerdes, Nikos Tsiknakis, Georgios C. Manikis, Artur Mezheyeuski, Jonas Bergh, Alexios Matikas, Theodoros Foukakis

Summary: The evaluation of breast cancer immune microenvironment is important in clinical practice, but the spatiotemporal organization of the anti-breast cancer immune response is not fully explored yet. Multiplex in situ methods with spectral imaging can deconvolute the different elements of tumor immune microenvironment and provide valuable information for classification and biomarker discovery. These methods enable the simultaneous evaluation of multiple targets and characterization of spatial organization of the tumor immune microenvironment.

CANCERS (2022)

Article Oncology

Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial

Alexios Matikas, Hemming Johansson, Per Gryback, Judith Bjohle, Balazs Acs, Ceren Boyaci, Tobias Lekberg, Hanna Fredholm, Ellinor Elinder, Sara Margolin, Erika Isaksson-Friman, Ana Bosch, Henrik Lindman, Jamila Adra, Anne Andersson, Susanne Agartz, Mats Hellstrom, Ioannis Zerdes, Johan Hartman, Jonas Bergh, Thomas Hatschek, Theodoros Foukakis

Summary: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ between the two groups. Here, we present the survival outcomes from PREDIX HER2 and investigate metabolic response and tumor-infiltrating lymphocytes (TIL) as prognostic factors.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Career and Professional Development for Young Oncologists

Maximilian J. Mair, Claudia Cardone, Liz Connolly, Maria Kfoury, Matteo Lambertini, Jonathan Lim, Elene Mariamidze, Alexios Matikas, Rille Pihlak, Kevin Punie, Christoph Oing, Rodrigo Sanchez-Bayona, Pawel Sobczuk, Hongcheng Zhu, Anna S. Berghoff, Teresa Amaral

Summary: Young oncologists worldwide face various challenges in their career and professional development, including time management, work-life balance, career progression, and educational opportunities. Professional societies have recognized these challenges and have designed specific programs to address them. The importance of this strategy cannot be overstated, as young oncologists make up almost 50% of the oncology workforce. However, recent surveys indicate that many young oncologists are considering alternative career paths due to burnout exacerbated by the COVID-19 pandemic and other challenges.

ONCOLOGY RESEARCH AND TREATMENT (2023)

Meeting Abstract Oncology

Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49

Peter Schmid, Joo Hyuk Sohn, Yolanda Jerez Gilarranz, Lucia Gonzalez-Cortijo, Amir Sonnenblick, Dhanusha Sabanathan, Ernesto Korbenfeld, Daniel Egle, Brigitte Poirier, Flora Zagouri, Alexios Matikas, Sercan Aksoy, Umut Demirci, Pier Ramos-Elias, Seock-Ah Im, Fatima Cardoso, Liyi Jia, Kim Hirshfield, Konstantinos Tryfonidis, Hope S. Rugo

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.

Ioannis Zerdes, Yajing Zhu, Evangelos Tzoras, Alexios Matikas, Jonas C. S. Bergh, Antonios Valachis, Theodoros Foukakis

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.

Yajing Zhu, Kang Wang, Ioannis Zerdes, Alexios Matikas, Mattias Bergqvist, Ellinor Elinder, Ana Bosch, Henrik Lindman, Zakaria Einbeigi, Anne Andersson, Lena Carlsson, Ann Charlotte Dreifaldt, Erika Isaksson-Friman, Mats Hellstrom, Hemming Johansson, Jonas C. S. Bergh, Thomas Hatschek, Theodoros Foukakis

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

Alexios Matikas, Hemming Johansson, Per Gryback, Judith Bjohle, Tobias Lekberg, Hanna Fredholm, Balazs Acs, Ellinor Elinder, Erika Isaksson-Friman, Susanne Agartz, Mats Hellstrom, Ioannis Zerdes, Johan Hartman, Jonas C. S. Bergh, Thomas Hatschek, Theodoros Foukakis

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer

Hope S. Rugo, Joohyuk Sohn, Yolanda Jerez Gilarranz, Lucia Gonzalez-Cortijo, Amir Sonnenblick, Dhanusha Sabanathan, Ernesto Pablo Korbenfeld, Daniel Egle, Brigitte Poirier, Flora Zagouri, Alexios Matikas, Sercan Aksoy, Umut Demirci, Pier Ramos-Elias, Seock-Ah Im, Fatima Cardoso, Liyi Jia, Carlos Baccan, Konstantinos Tryfonidis, Peter Schmid

JOURNAL OF CLINICAL ONCOLOGY (2022)

No Data Available